Comparative Pharmacology
Head-to-head clinical analysis: ADRENACLICK versus EPIPEN JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRENACLICK versus EPIPEN JR.
ADRENACLICK vs EPIPEN JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-1 receptor activation causes vasoconstriction, increasing blood pressure and reducing mucosal edema. Beta-1 receptor activation increases heart rate and contractility. Beta-2 receptor activation causes bronchodilation and vasodilation.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic effects include vasoconstriction, which reduces edema and increases blood pressure. Beta-adrenergic effects include bronchodilation, positive inotropic and chronotropic cardiac effects, and inhibition of histamine release from mast cells.
100 to 200 mcg sublingually as needed for severe allergic reaction, may repeat every 5-15 minutes.
Epinephrine 0.3 mg intramuscularly in the mid-outer thigh every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
2.0-2.5 hours in adults with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life is approximately 2-3 minutes following intravenous administration. Clinically, the short half-life necessitates repeat dosing or continuous infusion for sustained effect. After intramuscular injection, absorption is slower, and the effective half-life is longer due to continued absorption.
Primarily renal (80-90% as unchanged drug via glomerular filtration and active tubular secretion), with 10-20% fecal via biliary elimination.
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The metabolites, including metanephrine and vanillylmandelic acid (VMA), are primarily excreted renally. About 85-90% of an administered dose is eliminated in the urine within 24 hours, with less than 5% excreted unchanged. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist